ImmuVen was honored a Phase II Small Business Innovation Research (SBIR) accord totaling $1.68 million from the National Institute for Allergy and Infectious Disease (NIH) for carrying on with development of its therapeutic pipeline (IMV0123) against super antigens provided by methicillin-sensitive and methicillin-resistant Staphylococcal aureus. This award goes on the work previously sustained by an efficiently finished Phase I SBIR grant.
ImmuVen's bio-therapeutic method of neutralizing super antigen toxicity is distinctively introduced to intervene in deaths and morbidity attributable to super antigen production within a host of S. aureus problems such as pneumonia and endocarditis. The intention of this award would be to provide aid for bringing IMV0123 through a pre-Investigational New Drug (IND) meeting together with the Food and Drug Administration (FDA) alongside completing major milestones within the preclinical development of a typical therapeutic.
No comments:
Post a Comment